Immunofluorescent analysis of Integrin alpha 6 was performed on 90% confluent log phase MDCK cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0. 25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with ABfinity™ Integrin alpha 6 recombinant rabbit oligoclonal antibody (Product # 710209) at a dilution of 1:500 in 1% BSA and incubated for 3 hours at room temperature and then labeled with Alexa Flour® 488 goat anti-rabbit IgG secondary antibody (Product # A11008) at a dilution of 1:400 for 30 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). Panel c is a merged image showing localization at the cell junctions and panel d is a control without primary antibody. The images were captured using a Nikon microscope at 20X magnification.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant protein corresponding to amino acids 102–299 of human integrin, alpha 6|
|Contains||0.09% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 1 month. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:500-1:5000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
ABfinity™ recombinant antibodies are rabbit monoclonal antibodies, unmatched for producing superior results. ABfinity™ antibodies are developed by immunizing animals, screening for functionality, cloning the immunogen-specific antibody genes into high-level mammalian expression vectors, produced on a large scale and purified with Protein A.
ABfinity™ oligoclonal antibodies comprise a selection of multiple different recombinant monoclonal antibodies, providing the best of both worlds—the sensitivity of a polyclonal antibody with the specificity of a monoclonal, all delivered with the consistency only found in a recombinant antibody. While functionally the same as a polyclonal antibody—recognizing multiple epitope sites on the target and producing higher detection sensitivity for low abundance targets when compared with monoclonal antibodies—an oligoclonal antibody has a known mixture of light and heavy chains. This exact population can be produced in every lot, circumventing the biological variability typically associated with polyclonal antibody production.
Intact IgG appears on a non-reducing gel as ~150 kDa band and upon reduction generating a ~25 kDa light chain band and a ~50 kDa heavy chain.
Integrins are cell surface receptors that interact with the extracellular matrix and mediate intracellular signals that affect cellular shape, mobility, and progression through the cell cycle in response to the extracellular matrix. Integrin receptors are composed of alpha and beta subunits, and form structural and functional linkages between the ECM and intracellular cytoskeletal linker proteins. Signaling mediated by Intergrin/ ECM interactions are also integrated with cellular responses to growth factor signaling to regulate cellular proliferation, cytoskeletal reorganization and other responses necessary for cellular survival. Integrin alpha 6 is predominantly expressed by epithelia. It plays a critical structural role in the hemidesmosome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
RFX1 maintains testis cord integrity by regulating the expression of Itga6 in male mouse embryos.
710209 was used in immunohistochemistry - paraffin section to determine regulation of expression of Itga6 in male mouse embryos that controls RFX1 maintaining testis cord integrity
|Wang B,Qi T,Chen SQ,Ye L,Huang ZS,Li H||Molecular reproduction and development (83:606)||2016|
|Human||Not Cited||Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug.||Shin CS,Kwak B,Han B,Park K||Molecular pharmaceutics (10:2167)||2013|